{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:40:55Z","timestamp":1784896855819,"version":"3.55.0"},"reference-count":176,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Increasing antimicrobial resistance (AMR) is one of the leading causes of death worldwide. The predominant pathogens that exacerbate the AMR problem are multidrug-resistant (MDR) Gram-negative bacteria (GNB). Due to the increasing adaptation of MDR GNB to commercially available antimicrobial drugs, such as carbapenems as well as third- and fourth-generation cephalosporins, pharmaceutical companies around the world have been forced to produce increasingly innovative chemotherapeutics. Cefiderocol (CFDC) is a novel injectable cephalosporin 5 generation developed by Shionogi, directed against MDR GNB, including strains resistant to carbapenems. Results: Analysis demonstrated its significant efficacy across a wide range of in vitro and in vivo studies against MDR GNB, including Carbapenem-resistant Pseudomonas aeruginosa (CRPA), Carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Enterobacterales (CRE) (WHO Critical Priority Pathogens). Clinical studies have shown CFDC to be an effective drug with few adverse effects. Conclusions: When used CFDC appropriately within antibiotic stewardship guidelines, this drug is an effective, well-tolerated targeted treatment option for patients with severe clinical conditions.<\/jats:p>","DOI":"10.3390\/jcm14238415","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:19:51Z","timestamp":1764328791000},"page":"8415","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Therapeutic Potential of Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4777-4024","authenticated-orcid":false,"given":"Aleksandra","family":"Z\u0142otowska","sequence":"first","affiliation":[{"name":"The Students Scientific Association by Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria Hanna","family":"Buzun","sequence":"additional","affiliation":[{"name":"The Students Scientific Association by Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Pe\u0142ka","sequence":"additional","affiliation":[{"name":"The Students Scientific Association by Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Zalewska","sequence":"additional","affiliation":[{"name":"The Students Scientific Association by Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-4904","authenticated-orcid":false,"given":"Wies\u0142awa","family":"Duszy\u0144ska","sequence":"additional","affiliation":[{"name":"Department and Clinic of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Wroclaw Medical University, L. Pasteura Street 1, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025, April 29). Ten Threats to Global Health in 2019. Available online: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2147\/IDR.S234610","article-title":"Antimicrobial Resistance: Implications and Costs","volume":"12","author":"Dadgostar","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_3","unstructured":"European Centre for Disease Prevention and Control (2025, May 06). Carbapenem-Resistant Enterobacterales, Third Update\u20143 February 2025, Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/risk-assessment-carbapenem-resistant-enterobacterales-third-update-february-2025_0.pdf."},{"key":"ref_4","unstructured":"European Centre for Disease Prevention and Control (2025, May 06). Antimicrobial Resistance in the EU\/EEA (EARS-Net)\u2014Annual Epidemiological Report 2023, Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/antimicrobial-resistance-annual-epidemiological-report-EARS-Net-2023.pdf."},{"key":"ref_5","unstructured":"European Centre for Disease Prevention and Control and WHO Regional Office for Europe (2025, May 06). Surveillance of Antimicrobial Resistance in Europe, 2023 Data: Executive Summary, Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/379559\/9789289061544-eng.pdf?sequence=4."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Husna, A., Rahman, M.M., Badruzzaman, A.T.M., Sikder, M.H., Islam, M.R., Rahman, M.T., Alam, J., and Ashour, H.M. (2023). Extended-Spectrum \u03b2-Lactamases (ESBL): Challenges and Opportunities. Biomedicines, 11.","DOI":"10.3390\/biomedicines11112937"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","article-title":"Extended-spectrum \u03b2-lactamases: An update on their characteristics, epidemiology and detection","volume":"3","author":"Castanheira","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: A systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_9","first-page":"Doc05","article-title":"Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?","volume":"12","author":"Exner","year":"2017","journal-title":"GMS Hyg. Infect. Control."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mancuso, G., De Gaetano, S., Midiri, A., Zummo, S., and Biondo, C. (2023). The Challenge of Overcoming Antibiotic Resistance in Carbapenem-Resistant Gram-Negative Bacteria: \u201cAttack on Titan\u201d. Microorganisms, 11.","DOI":"10.20944\/preprints202307.0676.v1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1473-3099(11)70056-1","article-title":"Metallo-\u03b2-lactamases: A last frontier for \u03b2-lactams?","volume":"11","author":"Cornaglia","year":"2011","journal-title":"Lancet. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"Doi","year":"2017","journal-title":"Virulence"},{"key":"ref_13","first-page":"15","article-title":"Carbapenem resistance: Overview of the problem and future perspectives","volume":"3","author":"Meletis","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lau, M.Y., Ponnampalavanar, S., Chong, C.W., Dwiyanto, J., Lee, Y.Q., Woon, J.J., Kong, Z.X., Jasni, A.S., Lee, M.C.C., and Obaidellah, U.H. (2024). The Characterisation of Carbapenem-Resistant Acinetobacter baumannii and Klebsiella pneumoniaein a Teaching Hospital in Malaysia. Antibiotics, 13.","DOI":"10.3390\/antibiotics13111107"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4269\/ajtmh.22-0556","article-title":"Prevalence of Antimicrobial Resistance in Gram-Negative Bacteria Bloodstream Infections in Peru and Associated Outcomes: VIRAPERU Study","volume":"109","author":"Krapp","year":"2023","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.2020.2241","article-title":"Infection, Antibiotics, and Patient Outcomes in the Intensive Care Unit","volume":"323","author":"Yin","year":"2020","journal-title":"JAMA"},{"key":"ref_20","unstructured":"(2025, April 29). Multinational ICU Study Finds High Rate of Infection, Antibiotic use Chris Dall|News Reporter|CIDRAP News 25 March 2020 Antimicrobial Stewardship. Available online: https:\/\/www.cidrap.umn.edu\/antimicrobial-stewardship\/multinational-icu-study-finds-high-rate-infection-antibiotic-use."},{"key":"ref_21","unstructured":"World Health Organization (2025, April 29). 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240000193."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Terreni, M., Taccani, M., and Pregnolato, M. (2021). New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules, 26.","DOI":"10.3390\/molecules26092671"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New Perspectives on Antimicrobial Agents: Cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1103","DOI":"10.1093\/cid\/ciaa1799","article-title":"US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja\u00ae)","volume":"72","author":"Naseer","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107150","DOI":"10.1016\/j.ijantimicag.2024.107150","article-title":"Activity of cefiderocol and innovative \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double \u03b2-lactamases under high and low permeability conditions","volume":"63","author":"Aracil","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e38248","DOI":"10.1097\/MD.0000000000038248","article-title":"Risk factors and economic burden for community-acquired multidrug-resistant organism-associated urinary tract infections: A retrospective analysis","volume":"103","author":"Bian","year":"2024","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gauba, A., and Rahman, K.M. (2023). Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111590"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial Resistance in ESKAPE Pathogens","volume":"33","author":"Forde","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1098\/rstb.1980.0049","article-title":"The structure of beta-lactamases","volume":"289","author":"Ambler","year":"1980","journal-title":"Phil. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s15010-020-01520-6","article-title":"Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: An approach based on the mechanisms of resistance to carbapenems","volume":"48","author":"Karakonstantis","year":"2020","journal-title":"Infection"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Bedeni\u0107, B., Pospi\u0161il, M., Na\u0111, M., and Pavlovi\u0107, D.B. (2025). Evolution of \u03b2-Lactam Antibiotic Resistance in Proteus Species: From Extended-Spectrum and Plasmid-Mediated AmpC \u03b2-Lactamases to Carbapenemases. Microorganisms, 13.","DOI":"10.20944\/preprints202501.1426.v1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1128\/microbiolspec.VMBF-0016-2015","article-title":"Mechanisms of Antibiotic Resistance","volume":"4","author":"Munita","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nrmicro1994","article-title":"The porin and the permeating antibiotic: A selective diffusion barrier in Gram-negative bacteria","volume":"6","author":"James","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2217\/fmb.14.66","article-title":"Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance","volume":"9","author":"Blair","year":"2014","journal-title":"Future Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., Jubeh, B., and Karaman, R. (2020). Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It. Molecules, 25.","DOI":"10.3390\/molecules25061340"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1128\/AAC.34.9.1806","article-title":"Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-dependent iron transport system","volume":"34","author":"Silley","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/phar.2476","article-title":"Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens","volume":"40","author":"Alosaimy","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1060028020929988","article-title":"Cefiderocol: A Siderophore Cephalosporin","volume":"54","author":"Rizk","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.37201\/req\/s02.03.2022","article-title":"Antibacterial spectrum of cefiderocol","volume":"35","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37201\/req\/s02.02.2022","article-title":"Mechanism of action of cefiderocol","volume":"35","author":"Soriano","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Domingues, S., Lima, T., Saavedra, M.J., and Da Silva, G.J. (2023). An Overview of Cefiderocol\u2019s Therapeutic Potential and Underlying Resistance Mechanisms. Life, 13.","DOI":"10.3390\/life13071427"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1039\/D1MD00200G","article-title":"\u03b2-Lactam antibiotic targets and resistance mechanisms: From covalent inhibitors to substrates","volume":"12","author":"Lohans","year":"2021","journal-title":"RSC Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.37201\/req\/s01.07.2022","article-title":"Cefiderocol","volume":"35","author":"Soriano","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.37201\/req\/s02.07.2022","article-title":"Cefiderocol","volume":"35","author":"Mensa","year":"2022","journal-title":"Summary and conclusions. Rev. Esp. Quimioter."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.37201\/req\/s01.12.2021","article-title":"Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria","volume":"34","author":"Silva","year":"2021","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/cid\/ciab010","article-title":"US FDA\u2019s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication","volume":"73","author":"Echols","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00063-022-00925-5","article-title":"Klinische Erfahrungen mit Cefiderocol: Neue Therapieoption bei schweren Infektionen durch multiresistente gramnegative Erreger New therapeutic option for severe infections with multidrug resistant Gram-negative bacteria [Clinical experience using cefiderocol]","volume":"118","author":"Witzke","year":"2023","journal-title":"Med. Klin. Intensiv. Notfmed."},{"key":"ref_51","unstructured":"(2025, April 29). FDA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209445s009lbl.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dkae464","article-title":"Optimal dosage regimens of cefiderocol administered by short, prolonged or continuous infusion: A PK\/PD simulation study","volume":"80","author":"Goutelle","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_53","first-page":"e1065","article-title":"A New Dosing Frontier: Retrospective Assessment of Effluent Flow Rates and Residual Renal Function Among Critically Ill Patients Receiving Continuous Renal Replacement Therapy","volume":"6","author":"Lakshmipathy","year":"2024","journal-title":"Crit. Care Explor."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e01437-20","DOI":"10.1128\/AAC.01437-20","article-title":"Population Pharmacokinetic and Pharmacokinetic\/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection\/Sepsis, or Complicated Urinary Tract Infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.70010","article-title":"A review of antibiotic safety in pregnancy-2025 update","volume":"45","author":"Nguyen","year":"2025","journal-title":"Pharmacotherapy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37201\/req\/s02.04.2022","article-title":"Pharmacokinetics\/Pharmacodynamics and tolerability of cefiderocol in the clinical setting","volume":"35","year":"2022","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_57","unstructured":"NCBI Bookshelf (2025, September 15). Drugs and Lactation Database (LactMed\u00ae), Available online: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK559654\/."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s13054-024-05126-4","article-title":"Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support","volume":"28","author":"Frasquet","year":"2024","journal-title":"Crit. Care"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Booke, H., Friedrichson, B., Draheim, L., von Groote, T.C., Frey, O., R\u00f6hr, A., Zacharowski, K., and Adam, E.H. (2024). No Sequestration of Commonly Used Anti-Infectives in the Extracorporeal Membrane Oxygenation (ECMO) Circuit-An Ex Vivo Study. Antibiotics, 13.","DOI":"10.3390\/antibiotics13040373"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s13318-023-00840-w","article-title":"Cefiderocol is Not Sequestered in an Ex Vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit","volume":"48","author":"Berry","year":"2023","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/02676591231160462","article-title":"Pharmacokinetics of cefiderocol during extracorporeal membrane oxygenation: A case report","volume":"38","author":"Riera","year":"2023","journal-title":"Perfusion"},{"key":"ref_62","unstructured":"Pandey, N., and Cascella, M. (2023). Beta-Lactam Antibiotics. StatPearls, StatPearls Publishing."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40261-020-00955-x","article-title":"Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety","volume":"40","author":"Lee","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.nwh.2020.07.006","article-title":"Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria","volume":"24","author":"Weaver","year":"2020","journal-title":"Nurs. Womens Health"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects with Renal Impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: Focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00093-17","DOI":"10.1128\/AAC.00093-17","article-title":"In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","unstructured":"Fetcroja (cefiderocol) powder for concentrate for solution for infusion (2024). Summary of Product Characteristics, Shionogi B.V.. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fetcroja-epar-product-information_en.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e0019423","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s15010-025-02527-7","article-title":"Are cefiderocol or sulbactam\/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review","volume":"53","author":"Karakonstantis","year":"2025","journal-title":"Infection"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Golden, A.R., Adam, H.J., Baxter, M., Walkty, A., Lagac\u00e9-Wiens, P., Karlowsky, J.A., and Zhanel, G.G. (2020). In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Diagn. Microbiol. Infect. Dis., 97.","DOI":"10.1016\/j.diagmicrobio.2020.115012"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase-and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"dlae146","DOI":"10.1093\/jacamr\/dlae146","article-title":"Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections","volume":"6","author":"Shields","year":"2024","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: A phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","volume":"7","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"46","DOI":"10.37201\/req\/s01.11.2023","article-title":"Treatment guidelines for multidrug-resistant Gram-negative microorganisms","volume":"36","year":"2023","journal-title":"Rev. Esp. Quimioter."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"107186","DOI":"10.1016\/j.ijantimicag.2024.107186","article-title":"Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases","volume":"64","author":"Meschiari","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2147\/IDR.S150447","article-title":"Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae","volume":"11","author":"Petty","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"dlad152","DOI":"10.1093\/jacamr\/dlad152","article-title":"Activity of ceftolozane\/tazobactam, imipenem\/relebactam and ceftazidime\/avibactam against clinical Gram-negative isolates-SMART United States 2019\u20132021","volume":"6","author":"Karlowsky","year":"2024","journal-title":"JAC Antimicrob Resist."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: Results of the PERSEUS study","volume":"44","author":"Almirante","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_89","first-page":"e01801","article-title":"ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum \u03b2-Lactamases and Carbapenemases","volume":"63","author":"Jacobs","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","article-title":"Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime","volume":"71","author":"Shields","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","article-title":"Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales","volume":"12","author":"Kaye","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkx139","article-title":"Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections","volume":"72","author":"Sims","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined \u03b2-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014\u20132019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb. Drug Resist."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e0048621","DOI":"10.1128\/AAC.00486-21","article-title":"Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020","volume":"65","author":"Bhatnagar","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Mauri, C., Maraolo, A.E., Di Bella, S., Luzzaro, F., and Principe, L. (2021). The Revival of Aztreonam in Combination with Avibactam against Metallo-\u03b2-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics, 10.","DOI":"10.3390\/antibiotics10081012"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: A randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.diagmicrobio.2004.09.002","article-title":"Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia","volume":"51","author":"Zelenitsky","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eimc.2022.06.004","article-title":"Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria","volume":"41","author":"Pintado","year":"2023","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.2147\/IDR.S386641","article-title":"Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii with Special Reference to Carbapenemases: A Systematic Review","volume":"15","author":"Gupta","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.cmi.2022.03.014","article-title":"Exposure to World Health Organization\u2019s AWaRe antibiotics and isolation of multidrug resistant bacteria: A systematic review and meta-analysis","volume":"28","author":"Sulis","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e0018922","DOI":"10.1128\/aac.00189-22","article-title":"In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","first-page":"e01110","article-title":"New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections","volume":"63","author":"Isler","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e01698-20","DOI":"10.1128\/AAC.01698-20","article-title":"Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain","volume":"65","author":"Sime","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"106723","DOI":"10.1016\/j.ijantimicag.2023.106723","article-title":"Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: A real-life, single-centre experience","volume":"61","author":"Karruli","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"106376","DOI":"10.1016\/j.jinf.2024.106376","article-title":"Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID","volume":"90","author":"Soueges","year":"2025","journal-title":"J. Infect."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10096-024-04833-8","article-title":"Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: A single center, observational study","volume":"43","author":"Oliva","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","article-title":"Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19","volume":"62","author":"Russo","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1128\/AAC.01230-13","article-title":"Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems","volume":"57","author":"Zusman","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Schmid, A., Wolfensberger, A., Nemeth, J., Schreiber, P.W., Sax, H., and Kuster, S.P. (2019). Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-51711-x"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: An Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"El Ghali, A., Kunz Coyne, A.J., Lucas, K., Tieman, M., Xhemali, X., Lau, S.-p, Iturralde, G., Purdy, A., Holger, D.J., and Garcia, E. (2024). Cefiderocol: Early clinical experience for multi-drug resistant gram-negative infections. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.03108-23"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jiph.2023.06.009","article-title":"Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study","volume":"16","author":"Onorato","year":"2023","journal-title":"J. Infect. Public. Health."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Venuti, F., Romani, L., De Luca, M., Tripiciano, C., Palma, P., Chiriaco, M., Finocchi, A., and Lancella, L. (2023). Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review. Microorganisms, 11.","DOI":"10.3390\/microorganisms11071798"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Chiusaroli, L., Liberati, C., Caseti, M., Rulli, L., Barbieri, E., Giaquinto, C., and Don\u00e0, D. (2022). Therapeutic Options and Outcomes for the Treatment of Neonates and Preterms with Gram-Negative Multidrug-Resistant Bacteria: A Systematic Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081088"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/INF.0000000000004529","article-title":"Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old with Infections Treated with Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study","volume":"44","author":"Bradley","year":"2025","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/phar.2782","article-title":"Review of novel \u03b2-lactams and \u03b2-lactam\/\u03b2-lactamase inhibitor combinations with implications for pediatric use","volume":"43","author":"Olney","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2147\/IDR.S485450","article-title":"Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection","volume":"17","author":"Tarski","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"La Bella, G., Salvato, F., Minafra, G.A., La Bella, G., Salvato, F., Minafra, G.A., Bottalico, I.F., Rollo, T., Barbera, L., and Tullio, S. (2022). Successful Treatment of Aortic Endocarditis by Achromobacter xylosoxidans with Cefiderocol Combination Therapy in a Non-Hodgkin Lymphoma Patient: Case Report and Literature Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121686"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"dlad103","DOI":"10.1093\/jacamr\/dlad103","article-title":"Successful use of prolonged cefiderocol monotherapy for the treatment of a complex pleural abscess caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa","volume":"5","author":"Brookfield","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_125","first-page":"819","article-title":"Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cmi.2022.12.012","article-title":"ESCMID\/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery","volume":"29","author":"Righi","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"107120","DOI":"10.1016\/j.ijantimicag.2024.107120","article-title":"International guidelines for the treatment of carbapenem-resistant Gram-negative Bacilli infections: A comparison and evaluation","volume":"63","author":"Wang","year":"2024","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","article-title":"Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli","volume":"56","author":"Zeng","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14787210.2024.2311213","article-title":"Metallo-beta-lactamases: Mechanisms, treatment challenges, and future prospects","volume":"22","author":"Zakhour","year":"2024","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e00397-20","DOI":"10.1128\/AAC.00397-20","article-title":"Metallo-\u03b2-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline","volume":"64","author":"Boyd","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1128\/AAC.01989-12","article-title":"Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-\u03b2-lactamase producers","volume":"57","author":"Crandon","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Mantzarlis, K., Manoulakas, E., Papadopoulos, D., Katseli, K., Makrygianni, A., Leontopoulou, V., Katsiafylloudis, P., Xitsas, S., Papamichalis, P., and Chovas, A. (2025). Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused by Klebsiella pneumoniae Resistant to All Beta-Lactame\/Beta-Lactamase Inhibitor Combinations. Antibiotics, 14.","DOI":"10.3390\/antibiotics14080806"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Sader, H.S., Mendes, R.E., Arends, S.J.R., Doyle, T.B., and Castanheira, M. (2025). Activity of Aztreonam-avibactam and other \u03b2-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020\u20132022). BMC Pulm Med., 25.","DOI":"10.1186\/s12890-025-03500-8"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome \u03b2-Lactam Resistance Conferred by Metallo-\u03b2-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_135","first-page":"101175","article-title":"Mortality of metallo-\u03b2-lactamase-producing Enterobacterales bacteremias with combined ceftazidime-avibactam plus aztreonam vs. other active antibiotics: A multicenter target trial emulation","volume":"49","author":"Huespe","year":"2025","journal-title":"Lancet Reg Health Am."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e0134623","DOI":"10.1128\/aac.01346-23","article-title":"In vitro activity of meropenem-vaborbactam plus aztreonam against metallo-\u03b2-lactamase-producing Klebsiella pneumoniae","volume":"68","author":"Shashkina","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2147\/IDR.S306146","article-title":"Therapeutic Options for Metallo-\u03b2-Lactamase-Producing Enterobacterales [Corrigendum]","volume":"14","author":"Tan","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1128\/AAC.01870-15","article-title":"Correlation of \u03b2-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program","volume":"60","author":"Bradford","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"Lok","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cmi.2020.12.009","article-title":"Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins","volume":"27","author":"Wagenlehner","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: Systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e0106521","DOI":"10.1128\/AAC.01065-21","article-title":"Interactions of Polymyxin B in Combination with Aztreonam, Minocycline, Meropenem, and Rifampin against Escherichia coli Producing NDM and OXA-48-Group Carbapenemases","volume":"65","author":"Olsson","year":"2021","journal-title":"Antimicrob, Agents Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e00540-17","DOI":"10.1128\/mBio.00540-17","article-title":"Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era","volume":"8","author":"Bulman","year":"2017","journal-title":"mBio"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: A systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Timsit, J.F., Wicky, P.H., and de Montmollin, E. (2022). Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients. Antibiotics, 11.","DOI":"10.3390\/antibiotics11020144"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/gbe\/evx115","article-title":"Genomic Epidemiology of NDM-1-Encoding Plasmids in Latin American Clinical Isolates Reveals Insights into the Evolution of Multidrug Resistance","volume":"9","author":"Haggerty","year":"2017","journal-title":"Genome. Biol. Evol."},{"key":"ref_148","unstructured":"(2025, March 29). Research C for DE and FDA Drug Safety Communication: Increased risk of death with Tygacil (Tigecycline) compared to other antibiotics used to treat Similar Infections. FDA, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e00499-20","DOI":"10.1128\/AAC.00499-20","article-title":"Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018","volume":"64","author":"Lutgring","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1128\/AAC.00086-15","article-title":"Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem","volume":"59","author":"Oteo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s15010-017-1070-8","article-title":"Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: A case report and literature review","volume":"46","author":"Chibabhai","year":"2018","journal-title":"Infection"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J., van Duin, D., and Clancy, C.J. (2023). Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis., ciad428.","DOI":"10.1093\/cid\/ciad428"},{"key":"ref_153","unstructured":"Ast news update june 2023: New! (2023). Clsi m100-ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas Aeruginosa, Clinical & Laboratory Standards Institute. Available online: https:\/\/clsi.org\/about\/blog\/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa\/."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2018.10.023","article-title":"In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions","volume":"94","author":"Castanheira","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s40121-024-01044-8","article-title":"Navigating the Current Treatment Landscape of Metallo-\u03b2-Lactamase-Producing Gram-Negative Infections: What are the Limitations?","volume":"13","author":"Grabein","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e0044023","DOI":"10.1128\/aac.00440-23","article-title":"In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s10096-025-05080-1","article-title":"In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-\u03b2-lactamase producers","volume":"44","author":"Boattini","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.4629","article-title":"Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens","volume":"44","author":"Bleick","year":"2024","journal-title":"Pharmacotherapy"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Roye-Azar, M., Prater, M., Giuliano, C., and Kale-Pradhan, P.B. (2025). The Combination of Aztreonam-Avibactam in Multidrug-Resistant Gram-Negative Infections. Ann Pharmacother.","DOI":"10.1177\/10600280251366033"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Karruli, A., Migliaccio, A., Pournaras, S., Durante-Mangoni, E., and Zarrilli, R. (2023). Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii. Antibiotics, 12.","DOI":"10.3390\/antibiotics12121729"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fmb-2023-0248","article-title":"Sulbactam-durlobactam: A \u03b2-lactam\/\u03b2-lactamase inhibitor combination targeting Acinetobacter baumannii","volume":"19","author":"McLeod","year":"2024","journal-title":"Future Microbiol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/Durlobactam: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","article-title":"In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020\u20132021: A multicenter study","volume":"42","author":"Galani","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"106377","DOI":"10.1016\/j.ijantimicag.2021.106377","article-title":"In-vitro activity of cefiderocol, cefepime\/zidebactam, cefepime\/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017\u20132020","volume":"58","author":"Lee","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"106128","DOI":"10.1016\/j.ijantimicag.2020.106128","article-title":"In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany","volume":"56","author":"Kresken","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Shortridge, D., Streit, J.M., Mendes, R., and Castanheira, M. (2022). In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02712-21"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10096-023-04582-0","article-title":"Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25","volume":"42","author":"Findlay","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","article-title":"Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: A systematic review and meta-analysis","volume":"30","author":"Karakonstantis","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-394390-3.00002-1","article-title":"Structure, function and binding selectivity and stereoselectivity of siderophore-iron outer membrane transporters","volume":"69","author":"Schalk","year":"2012","journal-title":"Curr. Top. Membr."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e2221253120","DOI":"10.1073\/pnas.2221253120","article-title":"Interactions of TonB-dependent transporter FoxA with siderophores and antibiotics that affect binding, uptake, and signal transduction","volume":"120","author":"Chan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1128\/AAC.00831-15","article-title":"Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy","volume":"59","author":"Kim","year":"2015","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e01892-17","DOI":"10.1128\/JCM.01892-17","article-title":"Analysis of Potential \u03b2-Lactam Surrogates to Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae","volume":"56","author":"Hackel","year":"2018","journal-title":"J Clin. Microbiol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e00097-18","DOI":"10.1128\/AAC.00097-18","article-title":"TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates","volume":"62","author":"Luscher","year":"2018","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"20230707","DOI":"10.1515\/med-2023-0707","article-title":"Characteristics of antibiotic resistance mechanisms and genes of Klebsiella pneumoniae","volume":"18","author":"Li","year":"2023","journal-title":"Open Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14787210.2019.1647781","article-title":"Pharmacokinetics-pharmacodynamics of \u03b2-lactamase inhibitors: Are we missing the target?","volume":"17","author":"Monogue","year":"2019","journal-title":"Expert. Rev. Anti. Infect. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e4472","DOI":"10.1093\/cid\/ciaa1909","article-title":"Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic","volume":"73","author":"Streling","year":"2021","journal-title":"Clin. Infect. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8415\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:47:21Z","timestamp":1764330441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":176,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238415"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238415","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}